May 14: HIV prevention, distracted driving, LRT

The evidence supporting the use of Truvada for preventing HIV infection is well established, particularly for men who have sex with men. Clinical trials have demonstrated a protective effect over 90 per cent when used correctly. Use of PrEP is endorsed by the U.S. Centers for Disease Control and Prevention and by the World Health Organization as a component of HIV prevention strategies, and it should in no way be considered a controversial intervention.

In B.C., access to HIV treatment is provided provincially by the Ministry of Health PharmaCare program, while in most other provinces, insurers such as Blue Cross are expected to contribute to these costs. An insurance company denying access to a medication to prevent HIV infection, knowing they will be off the hook for covering the costs of HIV treatment in B.C. if an infection occurs, is nothing short of shameful.

Dr. Julio Montaner, Director of the BC Centre for Excellence in HIV/AIDS

Dr. Mark Hull, Researcher at the AIDS Research Program, Medicine Attending at the 10C AIDS Ward

Nathan Lachowsky, Researcher with the BC-Centre for Excellence in HIV/AIDS

Attempts to deter distracted driving welcome

Re: Hard line taken on distracted drivers, May 10

A very close dear friend and his wife were killed more than a year ago when their vehicle was hit by a delivery truck while its driver was texting with friends on a social media site with his handheld device. My friend’s three kids survived the collision.

I welcome the new set of fines and penalties the B.C. government introduced for distracted drivers. They may not be enough to serve as a strong deterrent, but regardless, they won’t bring my friend and his lovely wife back from the dead, both of whom I miss dearly, while his kids grow up without their parents’ love and support.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below